Compare State Street SPDR S&P Biotech ETF (XBI) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs YieldMax Universe Fund of Option Income ETFs — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.8 (market cap $10.11B), while YieldMax Universe Fund of Option Income ETFs trades at $7.62 (market cap $364M). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 27.8× YieldMax Universe Fund of Option Income ETFs's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| XBI | YMAX | |
|---|---|---|
Market Cap | $10.11B | $364M |
Volume | 12,903,266 | 1,181,378 |
Sector | Broad Market / Factor | Income / Options Overlay |
52-Week High | $169.55 | $12.98 |
52-Week Low | $104.99 | $7.27 |
Typical Hold Time | 38 Days | 56 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
YMAX trades at $7.61, up 1.06% with a bearish technical outlook. The ETF shows persistent NAV erosion despite weekly distributions, with the share price declining 22.7% year-to-date. Recent portfolio adjustments and a 40%+ annualized yield highlight structural concerns about distribution sustainability. Technical indicators show bearish moving averages and neutral oscillators with support at $7 and resistance at $8.
The outlook remains cautious due to ongoing principal erosion and high fees. While the high yield attracts income investors, the fund-of-funds structure adds layered costs. Analyst sentiment is neutral to bearish, with concerns about long-term viability outweighing short-term income benefits. Key risks include distribution policy sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
